Acadian Asset Management’s Harvard Bioscience HBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.1M Hold
179,614
﹤0.01% 1235
2026
Q1
$873K Buy
179,614
+2,351
+1% +$13.1K ﹤0.01% 1203
2025
Q4
$1.18M Buy
177,263
+70,294
+66% +$417K ﹤0.01% 1068
2025
Q3
$467K Buy
106,969
+3,046
+3% +$14.5K ﹤0.01% 1240
2025
Q2
$459K Sell
103,923
-3,784
-4% -$15.8K ﹤0.01% 1158
2025
Q1
$606K Buy
107,707
+7,828
+8% +$100K ﹤0.01% 1047
2024
Q4
$2.1M Buy
99,879
+12,518
+14% +$288K 0.01% 753
2024
Q3
$2.35M Sell
87,361
-8,950
-9% -$264K 0.01% 701
2024
Q2
$2.74M Sell
96,311
-4,099
-4% -$144K 0.01% 677
2024
Q1
$4.25M Sell
100,410
-575
-0.6% -$25.9K 0.01% 512
2023
Q4
$5.4M Sell
100,985
-5,401
-5% -$244K 0.02% 428
2023
Q3
$4.57M Sell
106,386
-4,139
-4% -$191K 0.02% 461
2023
Q2
$6.07M Hold
110,525
0.02% 402
2023
Q1
$4.64M Hold
110,525
0.02% 473
2022
Q4
$3.06M Buy
110,525
+2,687
+2% +$66.2K 0.02% 566
2022
Q3
$2.76M Buy
107,838
+2,955
+3% +$97.8K 0.02% 544
2022
Q2
$3.78M Sell
104,883
-1,848
-2% -$83.4K 0.02% 480
2022
Q1
$6.63M Sell
106,731
-7,060
-6% -$418K 0.03% 400
2021
Q4
$8.02M Sell
113,791
-542
-0.5% -$38.5K 0.03% 351
2021
Q3
$7.98M Buy
114,333
+6,767
+6% +$539K 0.03% 351
2021
Q2
$8.96M Buy
107,566
+5,579
+5% +$395K 0.03% 334
2021
Q1
$5.57M Sell
101,987
-7,677
-7% -$373K 0.02% 446
2020
Q4
$4.7M Buy
109,664
+680
+0.6% +$25.4K 0.02% 513
2020
Q3
$3.28M Sell
108,984
-1,154
-1% -$38.8K 0.01% 528
2020
Q2
$3.41M Buy
110,138
+2,942
+3% +$79.3K 0.01% 571
2020
Q1
$2.37M Buy
107,196
+1,149
+1% +$31.1K 0.01% 552
2019
Q4
$3.23M Sell
106,047
-2,130
-2% -$61.3K 0.01% 548
2019
Q3
$3.33M Buy
108,177
+2,974
+3% +$73.9K 0.01% 550
2019
Q2
$2.1M Buy
105,203
+28,129
+36% +$824K 0.01% 610
2019
Q1
$3.32M Sell
77,074
-3,821
-5% -$139K 0.01% 547
2018
Q4
$2.57M Sell
80,895
-4,565
-5% -$180K 0.01% 518
2018
Q3
$4.48M Buy
85,460
+170
+0.2% +$9.54K 0.02% 399
2018
Q2
$4.56M Buy
85,290
+489
+0.6% +$25K 0.02% 404
2018
Q1
$4.24M Buy
84,801
+14,147
+20% +$634K 0.02% 435
2017
Q4
$2.33M Sell
70,654
-322
-0.5% -$10.9K 0.01% 527
2017
Q3
$2.67M Sell
70,976
-2,581
-4% -$76.3K 0.01% 499
2017
Q2
$1.88M Sell
73,557
-316
-0.4% -$7.82K 0.01% 583
2017
Q1
$1.92M Sell
73,873
-2,301
-3% -$66.3K 0.01% 629
2016
Q4
$2.32M Hold
76,174
0.01% 561
2016
Q3
$2.07M Buy
76,174
+3,196
+4% +$88.7K 0.01% 531
2016
Q2
$2.09M Buy
72,978
+2,196
+3% +$69.8K 0.01% 513
2016
Q1
$2.14M Buy
70,782
+1,503
+2% +$42.6K 0.01% 528
2015
Q4
$2.4M Sell
69,279
-2,097
-3% -$71.7K 0.01% 544
2015
Q3
$2.7M Sell
71,376
-16,519
-19% -$769K 0.01% 497
2015
Q2
$5.01M Sell
87,895
-198
-0.2% -$11.3K 0.02% 408
2015
Q1
$5.13M Buy
88,093
+910
+1% +$48.9K 0.02% 391
2014
Q4
$4.95M Hold
87,183
0.02% 404
2014
Q3
$3.56M Buy
87,183
+40,287
+86% +$1.85M 0.02% 411
2014
Q2
$2.14M Buy
46,896
+36,089
+334% +$1.52M 0.01% 489
2014
Q1
$512K Buy
10,807
+1,859
+21% +$84.6K ﹤0.01% 668
2013
Q4
$421K Sell
8,948
-5,245
-37% -$229K ﹤0.01% 717
2013
Q3
$566K Sell
14,193
-12,372
-47% -$487K ﹤0.01% 614
2013
Q2
$947K Buy
+26,565
New +$1.02M 0.01% 497

Other funds holding HBIO

Acadian Asset Management's HBIO Position: Q2 2026 in Review

Acadian Asset Management held its Harvard Bioscience (HBIO) position steady in Q2 2026 at 179,614 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1235.

Acadian Asset Management first reported a position in HBIO in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.96M in Q2 2021. 34 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

  • Acadian Asset Management held 179,614 shares of Harvard Bioscience worth $1.1M as of Q2 2026.
  • Acadian Asset Management left its Harvard Bioscience share count unchanged in Q2 2026.
  • Harvard Bioscience made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1235 holding.
  • Acadian Asset Management first reported a position in Harvard Bioscience in Q2 2013 and has held it in 53 quarters since.
  • Acadian Asset Management's Harvard Bioscience position peaked at $8.96M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.